Back to top

Image: Bigstock

Will Repligen (RGEN) Gain on Rising Earnings Estimates?

Read MoreHide Full Article

Repligen (RGEN - Free Report) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.

The upward trend in estimate revisions for this drug developer reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Repligen, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate Revisions

The earnings estimate of $0.64 per share for the current quarter represents a change of +60% from the number reported a year ago.

Over the last 30 days, six estimates have moved higher for Repligen compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 23.47%.

Current-Year Estimate Revisions

For the full year, the earnings estimate of $2.69 per share represents a change of +63.03% from the year-ago number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Repligen. Over the past month, six estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 22.2%.

Favorable Zacks Rank

The promising estimate revisions have helped Repligen earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom Line

While strong estimate revisions for Repligen have attracted decent investments and pushed the stock 22.1% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Repligen Corporation (RGEN) - free report >>

Published in